What's in Theresa Zesiewicz, MD's pipeline?

Theresa Zesiewicz, MD has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Theresa Zesiewicz, MD's portfolio?

Top competitors by shared drug class: Mario Negri Institute for Pharmacological Research.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/theresa-zesiewicz-md.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Theresa Zesiewicz, MD — Portfolio Competitive Intelligence Brief

Theresa Zesiewicz, MD pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Gabapentin enacarbil extended release	Gabapentin enacarbil extended release	marketed
Gabapentin immediate release	Gabapentin immediate release	marketed	Anticonvulsant; gabapentinoid	Voltage-gated calcium channel alpha-2-delta subunit	Neurology

Therapeutic area mix

Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Mario Negri Institute for Pharmacological Research · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Theresa Zesiewicz, MD:

Cite this brief

Drug Landscape (2026). Theresa Zesiewicz, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/theresa-zesiewicz-md. Accessed 2026-05-16.